User:Mr. Ibrahem/Tapinarof
Clinical data | |
---|---|
Trade names | Vtama |
Other names | Benvitimod; GSK-2894512; (E)-3,5-Dihydroxy-4-isopropyl-trans-stilbene; 3,5-Dihydroxy-4-isopropylstilbene |
License data | |
Routes of administration | Topical |
Legal status | |
Legal status | |
Identifiers | |
| |
Chemical and physical data | |
Formula | C17H18O2 |
Molar mass | 254.329 g·mol−1 |
3D model (JSmol) | |
| |
|
Tapinarof, also known as benvitimod and sold under the brand name Vtama, is a medication used to treat plaque psoriasis.[1][2] It is applied to the skin.[1]
Common side effects include folliculitis, itchiness, and contact dermatitis.[1] It is an aryl hydrocarbon receptor activator.[1]
Tapinarof was approved for medical use in the United States in 2022.[1] It is not approved in either Europe or the United Kingdom as of 2022.[3] In the United States 60 grams of 1% cream costs about 1,400 USD as of 2022.[4]
References[edit]
- ^ a b c d e f g h "Vtama- tapinarof cream". DailyMed. 23 May 2022. Archived from the original on 3 July 2022. Retrieved 19 June 2022.
- ^ Stein Gold, Linda; Rubenstein, David S.; Peist, Ken; Jain, Piyush; Tallman, Anna M. (September 2021). "Tapinarof cream 1% once daily and benvitimod 1% twice daily are 2 distinct topical medications". Journal of the American Academy of Dermatology. 85 (3): e201–e202. doi:10.1016/j.jaad.2021.04.103.
- ^ "Tapinarof". SPS - Specialist Pharmacy Service. 29 August 2020. Archived from the original on 26 January 2022. Retrieved 12 December 2022.
- ^ "Vtama Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 12 December 2022.